Dapagliflozin reduces risk for hyperkalemia in HFrEF patients treated with MRAs: Study

Written By :  Dr. Shravani Dali
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2021-08-20 03:30 GMT   |   Update On 2021-08-20 03:31 GMT
Advertisement

Dapagliflozin Reduces Hyperkalemia Risk in Heart Failure and reduced ejection fraction (HFrEF) in patients treated with mineralocorticoid receptor antagonists (MRAs), according to a recent study presented at the European Society of Cardiology virtual congress.

Hyperkalaemia often limits the use of mineralocorticoid receptor antagonists (MRAs) in patients with heart failure and reduced ejection fraction (HFrEF), denying these patients a life-saving therapy. HFrEF is a complex clinical syndrome characterized by structural and/or functional impairment of the left ventricle, resulting in a decrease in heart pump function.

A study was conducted by Kristensen S et. al to determine whether treatment with the sodium-glucose cotransporter 2 (SGLT-2) inhibitor dapagliflozin reduces the risk of hyperkalaemia associated with MRA use in patients with HFrEF.

The researchers examined the risk of developing mild hyperkalaemia (potassium > 5.5 mmol/L) and moderate/severe hyperkalaemia (>6.0 mmol/L) in the Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure trial (DAPA-HF) according to background mineralocorticoid receptor antagonist (MRA) use, and randomized treatment assignment, by use of Cox regression analyses.

The results of the study are as follows:

  • Overall, 3370 (70.1%) patients in Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure trial (DAPA-HF) were treated with a mineralocorticoid receptor antagonist (MRA).
  • Mild hyperkalaemia and moderate/severe hyperkalaemia occurred in 182 (11.1%) and 23 (1.4%) patients treated with dapagliflozin as compared to 204 (12.6%) and 40 (2.4%) of patients given a placebo.
  • This yielded a hazard ratio (HR) of 0.86 for mild hyperkalaemia and 0.50 for moderate/severe hyperkalaemia, comparing dapagliflozin to placebo.

The researchers concluded that patients with Heart Failure and reduced ejection fraction (HFrEF) and taking a mineralocorticoid receptor antagonist (MRA) who were randomized to dapagliflozin had half the incidence of moderate/severe hyperkalaemia, compared with those randomized to placebo.

Reference

A study titled, "Dapagliflozin reduces the risk of hyperkalaemia in patients with heart failure and reduced ejection fraction": a secondary analysis DAPA-HF by Kristensen S et. al published at European Society of Cardiology virtual congress.

https://esc365.escardio.org/Congress/215836-dapagliflozin-reduces-the-risk-of-hyperkalaemia-in-patients-with-heart-failure-and-reduced-ejection-fraction-a-secondary-analysis-dapa-hf


Tags:    
Article Source : European Society of Cardiology virtual congress.

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News